Clinical Trial Update: Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study assessing the safety and tolerability of the indacaterol maleate/mometasone furoate combination delivered via the Twisthaler device over 14 days…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Indacaterol maleate (indacaterol)
• Mometasone furoate (Mometasone furoate)

Snippet

Sponsor: Novartis | Conditions: Asthma | Phase 2 | Status: COMPLETED | Results posted: 2013-04-22